Research programme: tissue kallikrein inhibitors - Dyax

Drug Profile

Research programme: tissue kallikrein inhibitors - Dyax

Alternative Names: DX-2300

Latest Information Update: 20 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dyax
  • Class Monoclonal antibodies
  • Mechanism of Action Tissue kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 01 Aug 2013 Discontinued - Preclinical for Inflammation in USA (Parenteral)
  • 29 Feb 2012 No development reported - Preclinical for Inflammation in USA (Parenteral)
  • 01 Jun 2007 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top